



Ablation for Atrial Fibrillation
Left ventricular systolic dysfunction by itself
does not inﬂuence outcome of atrial
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Aims The objective of the study was to analyse the inﬂuence of left ventricular (LV) ejection fraction (EF) on the outcomes
of atrial ﬁbrillation (AF) ablation after a ﬁrst procedure. Pre-procedural predictors of recurrences after AF ablation
can be useful for patient information and selection of candidates. The independent inﬂuence of LV systolic dysfunc-
tion on recurrence rate has not been studied.
Methods
and results
A case–control study (1:1) was conducted with a total of 72 patients: 36 cases (depressed LVEF) and 36 controls
(normal LVEF). Patients were matched by left atrial diameter (LAD), the presence of arterial hypertension,
and other variables that might inﬂuence the results (age, gender and paroxysmal vs. persistent AF). There
were no statistical differences in the variables used to perform the matching. Patients with depressed LVEF
had higher LV end diastolic diameter (55.6+6.2 vs. 52.4+5.5, P ¼ 0.03), higher LV end systolic diameter
(40.3+6.9 vs. 32.6+4.3, P , 0.001), lower LVEF (41.4+8.0 vs. 63.1+5.5, P , 0.001) and were more likely to
have structural heart disease. After a mean follow-up of 16+13 months, survival analysis for AF recurrences
showed no differences between patients with depressed vs. normal LVEF (50.0 vs. 55.6%, log rank ¼ 0.82). Cox
regression analysis revealed LAD to be the only variable correlated to recurrence [OR 1.11 (1.01–1.22),
P ¼ 0.03]. Analysis at 6 months showed a signiﬁcant increase in LVEF (43.23+7.61 to 51.12+13.53%, P ¼ 0.01)
for the case group.
Conclusion LV systolic dysfunction by itself is not a predictor of outcome after AF ablation. LAD independently correlates with
outcome in patients with low or normal LVEF.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
The establishment of catheter ablation treatment of ‘lone’
paroxysmal and persistent atrial ﬁbrillation (AF) using radiofre-
quency (RF) ablationled to attempts to expandthistreatment strat-
egy to heart failure (HF) populations with AF as the logical next
step.
1,2 However, reported success rates for RF ablation in HF
patients are clearly inferior to those in patients without structural
heart disease.
3,4 The reasons for this relative failure are unclear.
Published pre-procedural predictors of AF recurrence after RF
ablation include left atrial (LA) size, type and duration of AF and
age.
5–9 Of these, the most powerful and independent predictor
is LA size. As HF patients usually have LA dilatation concomitant
with left ventricular (LV) dysfunction, this could readily explain
the observed decrease in RF efﬁcacy. On the other hand, it is
also possible that HF patients suffer from a condition that leads
to a different mode of AF (through ﬁbrosis or other disease
of the LA), less responsive to pulmonary vein (PV) ablation.
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dictors of success to match patients with diminished left ventricular
ejection fraction (LVEF) undergoing circumferential PV ablation
(CPVA) to patients with normal LVEF and compared RF ablation
outcomes for the two groups.
Methods
Patient population
A case–control study (1:1) was conducted with a total of 72 patients,
36 consecutive cases (depressed LVEF, deﬁned as ,50%
10) and
36 controls (normal LVEF), retrospectively selected from our database.
During the period studied, 2003–2007, all ablations for depressed
ejection fraction (EF) cases were performed by the same two experi-
enced operators. Cardiac dimensions and EF were evaluated by one
full-time specialized physician, using 2-D transthoracic echocardiogra-
phy in a dedicated echo lab. If the patient was in AF during data acqui-
sition, the mean value of ﬁve consecutive beats was calculated,
minimizing the effect of the varying heart rate. Cases were matched
to controls by left atrial diameter (LAD), presence of arterial hyper-
tension (AHT), age, sex, and type of AF (paroxysmal vs. non-
paroxysmal). All patients were referred for percutaneous catheter
ablation of symptomatic AF after having failed treatment with at least
two antiarrhythmic drugs. Patients on oral anticoagulation stopped
medication 3 days prior to the procedure and low-molecular-weight
heparin was administered until the day before ablation. Patients under-
went transoesophageal echocardiography and cardiac magnetic reson-
ance (or computed tomography scan) prior to the ablation. Clinical
characteristics are shown in Table 1.
Circumferential pulmonary vein
ablation procedure
Catheters were introduced percutaneously through the femoral vein
and, after verifying the absence of a patent foramen ovale, a transseptal
puncture was performed to access the LA. After transseptal access, a
bolusofintravenousheparin(5000 IU)wasadministered,withadditional
bolustomaintainanactivatedclottingtime  200 sintheﬁrst18patients
and  250 s in the rest. The ablation procedure was performed under
deep sedation, using the CPVA technique previously described
5,11 for
both cases and controls. An electroanatomic mapping system
(CARTO, Biosense-Webster or NavX, St Jude Medical) generated a
three-dimensional map to support the creation and validation of RF
lesions during ablation. A thermocouple-equipped 8 mm or irrigated
tip catheter (Navistar, Biosense-Webster or Therapy Cool Path, St
Jude Medical) was used, with target temperatures of 558Ca t5 0W
maximum output and 458C at 40 W maximum output, respectively.
The ablation scheme consisted of continuous RF lesions to encircle
the left- and right-sided PV antrums, plus two ablation lines connecting
contralateral PV-encircling lesions through the LA roof and the inferior
aspect of the LA posterior wall, respectively. The end point of the pro-
cedure was the absence or dissociation of local electrograms inside the
surrounded regions. In addition, mitral isthmus ablation was anatomi-
cally performed by creating a RF line from the infero-lateral aspect
of the lateral PV circle to the mitral annulus.
Follow-up
Follow-up was performed on an ambulatory basis, with scheduled clini-
cal controls including ECG and Holter examinations at 3, 6, and
12 months. A repeat echo with the same acquisition method was per-
formed in all patients at 6 months after the AF ablation. At 3 months
follow-up (the end of the initial blanking period), antiarrhythmic drugs
were discontinued if possible. A successful outcome was deﬁned as
freedom from any episode of AF or atrial ﬂutter lasting more than
30 s after this initial 3-month blanking period, including asymptomatic
recurrence as evidenced by Holter examinations. Outcome was ana-
lysed after a single procedure. Survival and regression analysis did not
include datafromanyadditionalprocedurespatientsmayhaverequired.
Statistical analysis
All continuous data are expressed as mean+standard deviation (SD)
and were compared by Student’s t-test. Categorical values are
expressed as frequency or percentage and were compared using the
x
2 or Fisher’s exact test. Survival analysis was performed using the
log-rank test. Individual determinants of outcome were analysed
using univariable Cox regression analysis, after which two multivariable
Cox proportional-hazards models were developed. In the ﬁrst model,
all variables associated with a P-value  0.2 on univariable analysis were
evaluated using backward stepwise logistic regression (P , 0.1 for
entry and P . 0.05 for removal). The second model entered ﬁve vari-
ables with established clinical relevance: age, presence of hypertension,
type of AF, LAD, and EF. All variables in this model were entered in
...............................................................................................................................................................................
Table 1 Clinical characteristics of the patient population
Patients with normal LVEF (n 5 36) Patients with low LVEF (n 5 36) P-value
Age (years) 51.32+9.89 51.72+10.49 0.87
Male gender 34 (94.4) 32 (88.9) 0.67
Paroxysmal 15 (41.7) 14 (38.9) 1.0
AHT 19 (52.8) 19 (52.8) 1.0
Ischemic/idiopathic/hypertensive/valvular N/A 9/18/5/4 N/A
Duration of AF (months) 78.12+99.90 43.96+48.08 0.14
LVEDD (mm) 52.41+5.05 55.63+6.21 0.03
LVESD (mm) 32.64+4.28 40.29+6.95 ,0.001
LAD (mm) 42.81+5.43 42.61+6.00 0.89
EF (%) 63.14+5.47 41.36+8.02 ,0.001
AHT, Arterial hypertension; AF, Atrial ﬁbrillation; LVEDD, Left ventricular end diastolic diameter; LVESD, Left ventricular end systolic diameter; LAD, Left atrial diameter; EF,
Ejection fraction; mm, millimetres.
Continuous variables listed+standard deviation. Discontinuous variables listed with (percentage).
Left ventricular systolic dysfunction 25one step. Serial measurements were compared using repeated
ANOVA measures. An alpha level of 0.05 was deﬁned as the threshold
for rejecting the null hypothesis. All statistical analyses were performed





between cases and controls (Table 1). In the depressed LVEF group,
higherLVenddiastolicdiameter(55.6+6.2vs.52.4+5.5 mm, P ¼
0.03), higher LV end systolic diameter (40.3+6.9 vs. 32.6+
4.3 mm, P , 0.001) and lower LVEF (41.3+8.0 vs. 63.1+5.5%,
P , 0.001) were observed. Procedure times and RF time did not
differ signiﬁcantly between normal and low LVEF groups (133.1+
41.9 vs. 140.4+47.6 min and 2015+842 vs. 1929+1017 s,
respectively, P ¼ NS for both comparisons). In the control group,
16/36 (44%) patients were taking amiodarone before ablation, vs.
20/36 (55%) patients in the case group (P ¼ 0.4).
Outcomes and predictors of success
after AF ablation
The mean number of procedures for the entire population was
1.4+0.6, without differences between the two groups (1.38 for
cases vs. 1.36 for controls, P ¼ 0.89). After a mean follow-up of
16+13 months (range 6–59 months), there were no differences
between the normal and depressed LVEF groups in the arrhythmia-
free survival curves (Figure 1).
After a ﬁrst AF ablation procedure, 38/72 patients (52.8%) were
free of AF. Of 34 treatment failures, 26 redo procedures were per-
formed in 21 patients. In this group, success was ultimately
achieved in 12/21 patients (57.1%), bringing the total population
of patients free from AF to 50/72 (69.4%) (Table 2).
Table 3 lists all pre-procedural parameters that were compared
for successful and failed ablations. Univariable analysis found no
differences between groups in age, sex, clinical type of AF, and
presence of AHT or structural heart disease. Dichotomization of
normal and depressed LVEF also failed to predict successful
CPVA outcome (P ¼ 0.83). In contrast, LAD clearly differed
between patients with or without recurrences (Table 3): mean
LAD was 40.9+5.5 mm in the successful group and 44.7+
5.3 mm in the failed ablation group (P , 0.01). Cox regression
analysis of both models conﬁrmed that LAD was the only signiﬁ-
cant and independent predictor of a successful outcome after
CPVA [Model 1: OR 1.11 (1.03–1.20), P , 0.01; Model 2: OR
1.12 (1.04–1.20), P , 0.01)] (Table 2).
Evolution of systolic function
After 6 months follow-up of the low EF group, repeat echo
showed a signiﬁcant increase in EF, from 43.23+7.61 to
51.12+13.53% (P ¼ 0.01). There was no signiﬁcant interaction
between the outcome of the procedure and the change in EF
(P ¼ 0.75, Figure 2), although a trend could be observed toward
a somewhat less consistent improvement in the failed ablation
group. In the group with sinus rhythm after 6 months, mean EF
rose from 42.14 to 56.54% (P , 0.001) whereas the increase in
the recurrent AF group was 44.64–48.21% (P ¼ 0.28).
The evolution of systolic function was also analysed by type of
structural heart disease. In the case of ischemic heart disease,
the mean EF increased from 42.14+3.53 to 55.00+13.56 (n ¼
9, P ¼ 0.05). In the case of idiopathic dilated cardiomyopathy,
the mean EF improved from 42.64+8.91 to 52.07+11.93 (n ¼
18, P , 0.01). Finally, grouping all the non-idiopathic dilated cardi-
omyopathy patients, the EF increased from 44.31+4.29 to
52.38+12.35 (n ¼ 18, P ¼ 0.05).
Complications
There was no difference (P ¼ 0.61) in procedure-related compli-
cations (Table 4). In the case group, one transient coronary vasos-
pasm was observed. In the control group, two peripheral vascular
haematomas and one transient ischemic attack were observed. All
complications were treated conservatively and recovered
completely.
Figure 1 Kaplan–Meier curves (P Log rank test ¼ 0.82).
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Follow-up (months) 16.8+13.7 14.1+13.7 0.45
Success ﬁrst procedure 20 (55.6) 18 (50.0) 0.81
Successsecondprocedure 5/10 (50.0) 7/11 (63.6) 0.67
Total cure 25 (69.4) 25 (69.4) 1.00
LVEF, Left ventricular ejection fraction.
Continuous variables listed+standard deviation. Discontinuous variables listed
with (percentage).
T. De Potter et al. 26Figure 2 Changes in left ventricular ejection fraction (EF) after atrial ﬁbrillation ablation (Post), as compared with left ventricular ejection
fraction prior to the procedure (Pre) for each individual patient, and a comparison of the means.
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Table 3 Cox regression analysis of pre-procedural characteristics








Age 0.99 (0.96–1.02) 0.55 0.98 (0.93–1.02) 0.28
Gender 3.8 (0.52–27.88) 0.19 0.42
Paroxysmal vs. persistent 0.55 (0.27–1.14) 0.11 0.23 0.68 (0.31–1.48) 0.33
Duration of AF 1.00 (0.99–1.00) 0.37
AHT 1.12 (0.57–2.21) 0.73 1.19 (0.50–2.84) 0.69
RF time 1.00 (1.00–1.00) 0.59
LVESD 1.00 (0.95–1.05) 0.92
LVEDD 1.01 (0.96–1.07) 0.64
LAD 1.10 (1.03–1.16) 0.004 1.10 (1.03–1.16) 0.004 1.09 (1.02–1.16) 0.009
EF 0.99 (0.97–1.02) 0.65 0.78 0.99 (0.97–1.02) 0.83
HR, Hazard ratio; AF, Atrial ﬁbrillation; AHT, Arterial hypertension, RF, Radiofrequency, LVEDD, Left ventricular end diastolic diameter; LVESD, Left ventricular end systolic
diameter, LAD, Left atrial diameter, EF, Ejection fraction.
Left ventricular systolic dysfunction 27Discussion
AF and HF are two disease entities that share a remarkable bond,
inducing, sustaining, and aggravating each other.
12–14 Although
irregular and non-physiological ventricular rates in AF are detri-
mental to ventricular function, a poor ventricular contractile
state itself leads to structural and electrical atrial remodelling,
increasing the probability of developing AF. Both conditions
might be seen as part of a vicious circle in advanced HF. Much
attention is therefore drawn to the treatment of AF in HF patients,
both because they represent a vastly larger population than the
‘lone AF’ group and because there is at least a theoretical hope
that by treating AF some of the HF pathophysiology might also
be treated.
Although earlier studies such as RACE and AFFIRM failed to
show a beneﬁt of rhythm control strategies, and the recent
AF-CHF trial conﬁrmed these results for a low EF population,
these trials were focused on pharmacological treatment.
15–17
Strategies such as catheter ablation of AF might offer the beneﬁts
of rhythm control in HF without the drawbacks of most pharma-
ceutical regimens. Therefore, AF ablation has been well studied
in patients with low EF.
3,4,18–20 The only large series of these
trials (n ¼ 660) reports a clearly inferior ablation efﬁcacy in low
EF, whereas the smaller series document a non-signiﬁcant trend.
3
However, the reason for any lower ablation efﬁcacy is unclear.
Predictors of outcome
In the current study, we used a case–control matching design to
establish whether or not LV dysfunction itself independently con-
tributes to AF ablation failure or success. Considering the random
wavelet theories of AF maintenance, a parameter correlating in
some way with the amount of ﬁbrosis in the LA, such as LA dilata-
tion, would seem an attractive candidate for predicting procedural
success. In addition, recent publications studying populations with
more chronic forms of AF suggest that two types of treatment
strategies can be considered: Isolating the PVs to eliminate ectopy-
based triggering of AF from focal sources, seems to offer greater
success in patients without advanced LA disease; the alternative,
which is currently under intense evaluation for AF patients
suspected of having a large amount of atrial ﬁbrosis, would
be an approach focused on eliminating the substrate maintaining
AF.
21–23 Following this line of reasoning, the presence of a low
EF in a patient with a somewhat healthy LA should not impair
CPVA efﬁcacy. Results from this study clearly indicate that
indeed LAD independently predicts procedural success after
CPVA, and that a low EF by itself does not negatively impact
outcome.
Evolution of EF after ablation
In light of the aforementioned relationship between AF and HF, a
degree of improvement in LV function might be anticipated after
successful restoration of sinus rhythm. Studies in patients with
HF presumably due to sustained tachycardia (as seen in uncon-
trolled AF) do indeed establish the potential to reverse systolic
dysfunction after control of ventricular rate, whether through
regularization of rhythm or blocking of atrioventricular conduc-
tion.
4,18,19,24–26 Similarly, case reports have documented the exist-
ence of the entity dubbed tachycardiomyopathy in disease states
such as altered ventricular activation due to extreme incidence
of ventricular premature beats.
27,28 Interestingly, the present
results not only support a favourable EF evolution after successful
abolishment of AF, but also show EF evolution, similar in direction
although smaller in magnitude, in patients where CPVA had failed.
One possible explanation for this outcome is the strict deﬁnition of
recurrence as any AF episode during follow-up; a lesser AF burden
might positively inﬂuence EF evolution. On the other hand, conver-
sion to another type of atrial arrhythmia with a slower ventricular
rate might also have favourably impacted EF evolution in this group.
The improvement in LVEF may be considered a manifestation of
tachycardiomyopathy in the present patient cohort, where lower
mean ventricular rates during sinus rhythm may contribute to
the overall positive evolution of EF. In addition, the presence of
only moderate LV end diastolic enlargement with depressed EF
may be interpreted as an argument in favour of tachycardiomyopa-
thy. In most cases, no objective criterion for pre-procedural identi-
ﬁcation of isolated tachycardiomyopathy is available in low EF
patients. Therefore, we were not able to analyse the speciﬁc con-
tribution of this phenomenon to the overall outcome. However,
the LVEF improvement is very encouraging, showing that the
vast majority of patients with AF and LV systolic dysfunction
have at least some degree of tachycardiomyopathy. Indeed, LVEF
improvement was observed even in patients with ischemic heart
disease and did not differ from that of idiopathic LV dysfunction
patients. This result warrants further investigation with a larger
cohort of patients.
Limitations
The most important limitation of the study is the small sample size,
although it is statistically large enough to support the two main
ﬁndings: that a low EF by itself does not signiﬁcantly inﬂuence
the results of the procedure and that the strongest pre-procedural
predictor of AF ablation outcome is the atrial disease state, as
estimated by the presence of atrial dilatation, even in the presence
of HF.
Another potential limitation is that EF was evaluated during AF
before the procedure in some patients in persistent AF and during


















LVEF, Left ventricular ejection fraction; TIA, Transient ischemic attack.
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CPVAisfeasibleandsafeinpatientswithlowEF.Successratesaftera
ﬁrstprocedurearenotinferiortothoseforpatientswithnormalsys-
tolic function. Therefore, a low EF by itself does not preclude a suc-
cessful outcome. Rather, LAD is the strongest factor predicting
maintenance of sinus rhythm after AF ablation. In addition, EF has
the potential to increase after CPVA, which seems to hold true
both for successful and failed ablations, suggesting that the end
point might be the ‘AF burden’ reduction rather than ‘absence of
any AF episode’. Tachycardiomyopathy might be present in varying
degrees in most AF patients with low EF.
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